| scholarly article | Q13442814 |
| P50 | author | Martti Färkkilä | Q42383672 |
| P2093 | author name string | E Savilahti | |
| U Turunen | |||
| K-L Kolho | |||
| P Kärkkäinen | |||
| H Nuutinen | |||
| T Sipponen | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | feces | Q496 |
| Crohn's disease | Q1472 | ||
| P304 | page(s) | 1221-1229 | |
| P577 | publication date | 2008-08-26 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings | |
| P478 | volume | 28 |
| Q50870630 | A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. |
| Q51579592 | Aberrant Motility in Unaffected Small Bowel is Linked to Inflammatory Burden and Patient Symptoms in Crohn's Disease. |
| Q44405203 | Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists |
| Q46750779 | Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. |
| Q37703514 | Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. |
| Q43951967 | An observational study of cognitive function in patients with irritable bowel syndrome and inflammatory bowel disease |
| Q38040831 | Antimicrobial peptides and colitis |
| Q36193147 | Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? |
| Q43729604 | Assessment of the response of patients with Crohn's disease to biological therapy using new non-invasive markers: lactoferrin and calprotectin |
| Q91650453 | Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease |
| Q35840853 | Biomarkers in inflammatory bowel disease: current practices and recent advances |
| Q38215501 | Biomarkers in management of inflammatory bowel disease |
| Q36052700 | Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine |
| Q90339285 | British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults |
| Q34110399 | Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study |
| Q39311549 | Calprotectin in Daily Practice: Where Do We Stand in 2017? |
| Q37825812 | Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease |
| Q33998635 | Can chronic gastritis cause an increase in fecal calprotectin concentrations? |
| Q52372411 | Can faecal calprotectin predict relapse in inflammatory bowel disease: a mini review. |
| Q92589685 | Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science |
| Q37007065 | Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view. |
| Q38190411 | Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. |
| Q90052488 | Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease |
| Q41741168 | Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohn's Disease |
| Q40052049 | Comparison of Fecal Inflammatory Markers in Crohn's Disease |
| Q33752808 | Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation |
| Q33695598 | Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease |
| Q38923621 | Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials |
| Q36251799 | Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis |
| Q47134738 | Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization. |
| Q96231760 | Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease |
| Q41180309 | Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease |
| Q37630737 | Diagnostic advances in inflammatory bowel disease (imaging and laboratory). |
| Q28085134 | Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives |
| Q37592740 | Diffusion-weighted imaging for evaluating inflammatory activity in Crohn's disease: comparison with histopathology, conventional MRI activity scores, and faecal calprotectin. |
| Q38677581 | Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology? |
| Q26777553 | Disease monitoring in inflammatory bowel disease |
| Q47747881 | Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study |
| Q64243936 | Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease?: a systematic review |
| Q40338595 | Dynamics of the human gut microbiome in inflammatory bowel disease. |
| Q44512440 | EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging |
| Q51649850 | Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease. |
| Q47100161 | Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China |
| Q54335763 | Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis. |
| Q38896550 | Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases |
| Q55364545 | Emerging concepts in non-invasive monitoring of Crohn's disease. |
| Q53544370 | Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn's Disease. |
| Q26470550 | Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease |
| Q57111292 | Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin |
| Q57063313 | Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice |
| Q41407071 | Faecal biomarkers for screening small bowel inflammation in patients with Crohn's disease: a prospective study. |
| Q33695435 | Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: A prospective pilot study. |
| Q24608254 | Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis |
| Q89699485 | Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease |
| Q26776145 | Faecal calprotectin: Management in inflammatory bowel disease |
| Q53208202 | Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases. |
| Q41059819 | Faecal leukocyte esterase activity is an alternative biomarker in inflammatory bowel disease |
| Q53176388 | Fecal Calprotectin: Diagnostic Accuracy of the Immunochromatographic CalFast Assay in a Pediatric Population. |
| Q53246908 | Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohn's Disease. |
| Q38918650 | Fecal biomarkers in inflammatory bowel disease: how, when and why? |
| Q38219444 | Fecal biomarkers in the diagnosis and monitoring of Crohn's disease. |
| Q43573977 | Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy |
| Q53914270 | Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. |
| Q34990546 | Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation |
| Q38293787 | Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease |
| Q37618733 | Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use. |
| Q83587119 | Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease |
| Q55409323 | Fecal calprotectin reflects endoscopic activity in patients with small-bowel Crohn's disease according to double-balloon endoscopy findings. |
| Q92481892 | Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease |
| Q37492482 | Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations |
| Q33920587 | High-sensitivity C-reactive protein in paediatric inflammatory bowel disease |
| Q38668188 | Histologic scoring indices for evaluation of disease activity in Crohn's disease. |
| Q41504176 | Impact of disease location on fecal calprotectin levels in Crohn's disease |
| Q26749323 | Implementation of the simple endoscopic activity score in crohn's disease |
| Q47961270 | Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches |
| Q35582808 | Is faecal calprotectin equally useful in all Crohn's disease locations? A prospective, comparative study |
| Q57804048 | Limitations of Fecal Calprotectin At Diagnosis in Untreated Pediatric Crohnʼs Disease |
| Q40038096 | Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease |
| Q43696185 | Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission |
| Q38636313 | Luminally expressed gastrointestinal biomarkers. |
| Q38966323 | Management of post-operative Crohn's disease in 2017: where do we go from here? |
| Q33668961 | Measuring disease activity in Crohn's disease: what is currently available to the clinician |
| Q37986622 | Medical therapy for pediatric inflammatory bowel disease |
| Q94467560 | MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease |
| Q38823295 | MicroRNA-320a Strengthens Intestinal Barrier Function and Follows the Course of Experimental Colitis |
| Q55105117 | Monitoring Crohn's disease activity: endoscopy, fecal markers and computed tomography enterography. |
| Q38657630 | Monitoring and detection of disease recurrence after resection for Crohn's disease: the role of non-invasive fecal biomarkers |
| Q37795654 | Mucosal Healing in Inflammatory Bowel Disease: Where Do We Stand? |
| Q26852447 | Mucosal healing and deep remission: what does it mean? |
| Q45092694 | Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease |
| Q38005972 | Mucosal healing in Crohn's disease: a systematic review |
| Q36578893 | Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. |
| Q38266205 | Multidisciplinary management of gastrointestinal fibrotic stenosis in Crohn's disease. |
| Q43558561 | Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases |
| Q38986222 | New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes |
| Q39464033 | Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease |
| Q37698973 | Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update |
| Q27007083 | Optimising monitoring in the management of Crohn's disease: a physician's perspective |
| Q39338382 | Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up |
| Q38129088 | Paediatric gastrointestinal conditions and their oral implications |
| Q35767904 | PillCam COLON 2 in Crohn's disease: A new concept of pan-enteric mucosal healing assessment |
| Q88196220 | Practical guidance on the use of faecal calprotectin |
| Q38692263 | Preclinical and Undiagnosed Crohn's Disease: The Submerged Iceberg |
| Q40729580 | Predicting Endoscopic Disease Activity in Crohn's Disease: A New and Validated Noninvasive Disease Activity Index (The Utrecht Activity Index). |
| Q47340208 | Psychological Factors May Play an Important Role in Pediatric Crohn's Disease Symptoms and Disability. |
| Q37442760 | Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. |
| Q47743116 | Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease |
| Q50859208 | Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. |
| Q33763285 | Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies |
| Q57802005 | Recruitment of Activated Neutrophils Correlates with Disease Severity in Adult Crohn's Disease |
| Q37937183 | Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease |
| Q38160764 | Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring |
| Q33840425 | Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis |
| Q58806562 | Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity |
| Q48020566 | Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. |
| Q42857508 | Targeting mucosal healing in Crohn's disease |
| Q64969854 | Targeting mucosal healing in Crohn's disease: what the clinician needs to know. |
| Q36408869 | The Efficacy of Probiotic (Lactobacillus rhamnosus GG) and 5-ASA (Aminosalicylic Acid) in the Treatment of Experimental Radiation Proctitis in Rats |
| Q22241776 | The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for Crohn's disease: A 5-year prospective cohort study |
| Q39612269 | The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease |
| Q34456258 | The role and utility of faecal markers in inflammatory bowel disease |
| Q38171862 | The use of fecal calprotectin as a biomarker in gastrointestinal disease |
| Q37870433 | The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease |
| Q99349994 | Ulcerative colitis |
| Q38694153 | Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice |
| Q45042350 | Upregulation of circulating components of the alternative renin-angiotensin system in inflammatory bowel disease: A pilot study |
| Q34809416 | Usefulness of C-reactive protein as a disease activity marker in Crohn's disease according to the location of disease |
| Q36461010 | Utility of faecal calprotectin analysis in adult inflammatory bowel disease |
| Q34819062 | Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? |
| Q35498214 | Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease |
| Q41253661 | Vitamin D Status Is Associated with Intestinal Inflammation as Measured by Fecal Calprotectin in Crohn's Disease in Clinical Remission |
Search more.